摘要
BackgroundPrevious studies have shown that monotherapy with apatinib, an oral tyrosine kinase inhibitor, has promising efficacy for treating recurrent or metastatic (RM) nasopharyngeal carcinoma (NPC) patients. In this study, we aimed to assess the efficacy and safety of apatinib combined with capecitabine as a second-line therapy or beyond for treating RM-NPC patients who failed the first-line platinum-based chemotherapy.MethodsIn this single-arm, phase II study, we enrolled RM-NPC patients who had at least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1). The sample size was determined using Simon's two-stage design. All patients were administered with apatinib 500 mg once daily and capecitabine 1000 mg/m(2) twice per day on days 1-14 of each 21-day cycle. The primary endpoint was the objective response rate (ORR), and the secondary endpoints comprised disease control rate (DCR), duration of response (DoR), progression-free survival (PFS), overall survival (OS), and safety.ResultsWe enrolled 64 patients from September 2018 to August 2020. The ORR and DCR were 39.1% (95% CI, 27.1-52.1) and 85.9% (95% CI, 75.0-93.4), respectively. The median DoR was 14.4 months (95% CI, 7.8-21.0). As of April 20, 2021, the median follow-up duration was 12.0 months. The median PFS was 7.5 months (95% CI, 5.0-10.0) and the median OS was 15.7 months (95% CI, 11.3-20.1). The most common toxicities of any grade were anemia (75.0%), hand-foot syndrome (65.6%), and proteinuria (64.0%). Grade 3-4 toxicities were observed in 36 (56.3%) patients, with hypertension (14.1%), mucositis (12.4%), and fatigue (10.9%) most commonly observed.ConclusionsApatinib plus capecitabine shows promising efficacy as a second-line treatment option in pretreated platinum-refractory RM-NPC patients. Dose selection of this combination needs further investigation considering the toxicity.
学科与关键词
- Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II StudyDing, Xi; Zhang, Wei-Jing; You, Rui; Zou, Xiong; Wang, Zhi-Qiang; Ouyang, Yan-Feng; Peng, Lan; Liu, You-Ping; Duan, Chong-Yang; Yang, Qi; Lin, Chao; Xie, Yu-Long; Chen, Si-Yuan; Liu, Yong-Long; Gu, Chen-Mei; Xie, Ruo-Qi; Huang, Pei-Yu; Hong, Ming-Huang; Hua, Yi-Jun; Chen, Ming-YuanJournal of Clinical Oncology, 2023, 41(14): 2571-+.被引 15
- 吉西他滨联合阿帕替尼二线治疗复发转移性鼻咽癌疗效及安全性分析陈少卿; 黎军和; 余永春; 胡明斌; 刘运炜; 严俊峰Chinese Journal of Cancer Prevention and Treatment, 2019, (20): 1547-1550.
- Evaluation of second-line apatinib plus irinotecan as a treatment for advanced gastric adenocarcinoma or gastroesophageal conjunction adenocarcinoma: a prospective, multicenter phase II trialQu, Jinglei; He, Xin; Luo, Ying; Yu, Ping; Chen, Ying; Liu, Jing; Wang, Xin; Wang, Chang; Liang, Tingting; Bai, Yuxian; Han, Yu; Man, Li; Leng, Chuanchun; Zhou, Caiyun; He, Lijie; Liu, Yunpeng*; Qu, Xiujuan*Frontiers in Oncology, 2023, 13: 1072943.
